A scientist from the Francis Crick Institute has made a
groundbreaking discovery in understanding how the genetic
complexity of tumours can be recognised and exploited by the immune
system, even when the disease is at its most advanced
stages.
Professor Charles Swanton, from the Crick, jointly led the
research with Dr Sergio Quezada, head of the Immune Regulation and
Cancer Immunotherapy lab at the UCL Cancer Institute.
The research, published in Science on Thursday,
could guide future immunotherapies and improve the way existing
immunotherapy drugs are used.
As a tumour develops, the diversity of its genetic faults
can be flagged on the cancer cell surface, as unique mutations
appear in different parts of the tumour.
Crucially, by analysing data from hundreds of patients
from previous studies, researchers found that some of these flags -
known as antigens - represent the very earliest mutations of the
disease and are displayed on all cells in the tumour, rather than a
subset of tumour cells.
Then, in the lab, they isolated specialised immune cells,
called T-cells, from samples of two patients with lung cancer that
can recognise these common flags present on every tumour
cell.
Although they have the potential to wipe out all cancerous
cells within the tumour, these potent immune cells are switched off
by the tumour's defences.
This research paves the way for therapies that
specifically activate these T cells to target all the tumour cells
at once based on the disease's genetic signature. In the future,
scientists could exploit this by developing a therapeutic vaccine
to activate T-cells, or harvesting, growing and administering
T-cells back into the patient that recognise the antigens common to
every cancer cell.
Professor Charles Swanton said: "This is exciting. There
was evidence that complex tumours with many mutations could
increase the chance of the immune system spotting them; now we can
prioritise and target tumour antigens that are present in every
cell, the Achilles heel of these highly complex cancers.
"This opens up a way to look at individual patients'
tumours and profile all the antigen variations to figure out the
best ways for immunotherapy treatments to work, prioritising
antigens present in every tumour cell and identifying the body's
immune T cells that recognise them. This is really fascinating, and
takes personalised medicine to its absolute limit where each
patient would have a unique, bespoke treatment."
Dr Quezada added: "For many years we have studied how the
immune response to cancer is regulated without a clear
understanding of what it is that immune cells recognise
on cancerous cells. Based on these new findings, we will be able to
tell the immune system how to specifically recognise and attack
tumours."
The research was funded by Cancer Research UK and the
Rosetrees Trust.